BI 765063 + ezabenlimab + cetuximab

This drug is a combination therapy consisting of three monoclonal antibodies: - **BI 765063**: A first-in-class monoclonal antibody inhibitor targeting SIRPα (Signal-regulatory protein alpha) on myeloid cells. It disrupts the SIRPα/CD47 “don’t eat me” pathway, enhancing phagocytosis of tumor cells and promoting anti-tumor immune responses. Developed originally by OSE Immunotherapeutics and further developed in partnership with Boehringer Ingelheim[1]. - **Ezabenlimab (BI 754091)**: An anti–PD-1 monoclonal antibody (programmed cell death protein 1 inhibitor), enhancing T-cell mediated antitumor immune responses[1]. - **Cetuximab**: An anti–EGFR (epidermal growth factor receptor) monoclonal antibody, approved for the treatment of several epithelial tumors such as colorectal cancer and head/neck cancers. It blocks signal transduction pathways involved in cancer cell proliferation. The combination is under investigation for synergistic immunotherapeutic effects in solid tumors, including colorectal, endometrial, and head and neck cancers[1][3].